Recruitment is underway in an open-label ascending dose Phase 1 clinical trial evaluating Editas Medicine’s (EDIT +1.2%) CRISPR gene therapy AGN-15187 (EDIT-101) in patients with a rare inherited eye disorder called Leber congenital amaurosis type 10 (LCA10) characterized by severe visual impairment.
LCA10 is caused by mutation in a gene called CEP290. AGN-15187 is designed to eliminate this mutation.
The estimated completion date is March 2024.
Shares are up 1% premarket.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.